EAM
SAGE

EverPoint Asset Management’s Sage Therapeutics SAGE Stock Holding History

EverPoint Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$7.4M Sell
145,000
-105,000
-42% -$4.95M 0.14% 177
2016
Q3 		$11.5M Hold
250,000
– – 0.21% 126
2016
Q2 		$7.53M Buy
+250,000
New +$8.34M 0.15% 180

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EverPoint Asset Management's SAGE Position: Q4 2016 in Review

EverPoint Asset Management reduced its Sage Therapeutics (SAGE) stake by 42% in Q4 2016, selling an estimated $4.95M and leaving 145,000 shares worth $7.4M. The position accounts for 0.14% of the portfolio, ranked #177.

EverPoint Asset Management first reported a position in SAGE in Q2 2016 and has held it in 3 quarters since. The position peaked at $11.5M in Q3 2016. 166 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

  • EverPoint Asset Management held 145,000 shares of Sage Therapeutics worth $7.4M as of Q4 2016.
  • EverPoint Asset Management sold 105,000 Sage Therapeutics shares in Q4 2016, an estimated $4.95M.
  • Sage Therapeutics made up 0.14% of EverPoint Asset Management's portfolio in Q4 2016, its #177 holding.
  • EverPoint Asset Management first reported a position in Sage Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • EverPoint Asset Management's Sage Therapeutics position peaked at $11.5M in Q3 2016.
  • 166 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.